Improving CAR-T therapies for Acute Myeloid Leukemia
Engineering best in class Acute Myeloid Leukemia (AML) CAR-T therapies by enhancing persistence and defining the immune landscape of AML
This study is working on a new type of treatment for people with Acute Myeloid Leukemia (AML) to make it safer and more effective, so patients can have a better chance of recovery and less risk of the cancer coming back.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10998336 on NIH RePORTER |
What this research studies
This research focuses on enhancing CAR-T cell therapies specifically for patients with Acute Myeloid Leukemia (AML), a type of blood cancer with low survival rates. The project aims to address challenges such as the lack of specific antigens for AML and the toxicities associated with current treatments. By developing a new cellular therapy platform, the research seeks to improve T-cell persistence and reduce the risk of relapse. Patients may benefit from a more effective and targeted treatment option that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Acute Myeloid Leukemia who have not responded well to existing therapies.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with Acute Myeloid Leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with Acute Myeloid Leukemia, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in enhancing CAR-T therapies for blood cancers, but this specific approach for AML is relatively novel.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Rampersaud, Sham — University of California, San Francisco
- Study coordinator: Rampersaud, Sham
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.